Thursday 16 October, 2025
Objectives: Intravenous glucose tolerance tests (IVGTT) have been widely used to investigate the glucose-insulin interaction in subjects with and without…
Read morePoster: Drug/Disease Modelling - Endocrine
Development of a pharmacokinetic model to predict disposition of Dutasteride in zebrafish embryos
Thursday 16 October, 2025
Objectives: In the last two decades, the zebrafish and especially its embryos gained a lot of interest as animal models…
Read moreQuantifying the rate of blood glucose changes over the acute stage of ischemic stroke among patients with diabetes.
Thursday 16 October, 2025
Objectives: Hyperglycemia (HG) during acute ischemic stroke (AIS) is associated with poor outcomes. Diabetes mellitus (DM) is an independent predictor…
Read moreEnhanced pharmacometrics model utilizes heart rate to monitor thyroid function in pediatric Graves’ disease under pharmacotherapy
Thursday 16 October, 2025
Objectives: Graves’ disease (GD) with onset in childhood or adolescence is a serious pediatric rare disease (ORPHA:525731). Leading clinical signs…
Read morePharmacometrics Time-to-Event (TTE) Modeling of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients
Thursday 16 October, 2025
Objectives: Time-to-event (TTE) pharmacometrics analysis has an important role in the parametric quantification of the occurrence of diabetic nephropathy. Incorporating…
Read moreModel-Based Translational Rapamycin Dose Selection to Promote Engraftment and Expansion of the Engineered Regulatory T cell (EngTreg) product GNTI-122 in Human
Thursday 16 October, 2025
Objectives: Functional and/or absolute interleukin-2 (IL-2) scarcity is implicated in many autoimmune diseases and significantly impairs regulatory T cells (Tregs)…
Read moreM-EASE-2: A Modelling and simulation study conducted to further characterize the efficacy of low-dose Empagliflozin as Adjunctive to inSulin thErapy (M-EASE) in Type 1 Diabetes Mellitus (T1DM)
Thursday 16 October, 2025
Objectives: The objective of this modelling and simulation study was to further characterize the empagliflozin (EMPA) 2.5 mg qd dose…
Read moreBlood glucose profile evaluation with model-based approach using continuous glucose monitoring data
Thursday 16 October, 2025
Introduction: Continuous glucose monitoring (CGM) has revolutionized type 1 (T1D) and type 2 (T2D) diabetes management, as it provides real-time,…
Read moreDiabetes progression modelling of competing risks of long-term complications and mortality using Swedish registry data
Thursday 16 October, 2025
Objectives: Type 2 diabetes mellitus (T2D) is a group of metabolic diseases that are associated with long-term damage to and…
Read moreA population pharmacokinetic model of Glimepiride(Amaryl®)
Thursday 16 October, 2025
Objectives: Glimepiride is an oral hypoglycemic agent used to treat type II diabetes mellitus (T2DM). Glimepiride directly stimulates insulin secretion…
Read more